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INTRODUCTION : Fluindione (2-(4’fluoro-phenyl)-phenylindan1,3-dione) is
an anti-vitamin K (AVK) marketed in 1967 in France and in Luxembourg (1-3). It
is still the leading AVK in France in 2016 (around 800.000 patients, 82% of the
market). However very little is known on the metabolism of this drug. In order to
better understand the pharmacokinetics of this drug (4,5), we started to study the
in vitro and in vivo metabolism of fluindione. The results below show a series of
new metabolites both in vitro and in vivo.
METHODS: In vivo : Sprague Dawley rats weighting 200- 400 g were injected
IP with fluindione (5 mg/mL solution in sodium bicarbonate) at 5 or 20 mg/kg.
Blood was obtained at the tail at selected time and urine was collected.
In Vitro : Rat or human liver microsomes or recombinant Cytochrome P450
(CYP) (Supersomes Gentest) were incubated with fluindione (100 and 200 µM)
for 10 to 60 min in presence of NADPH generating system. Reactions were
stopped with one volume of CH3CN/AcOH 9:1, centrifuged at 13000 g and
supernatants were analyzed by HPLC/MS on a LCQ Advantage system or an
Exactive Orbitrap (Thermo) using negative ESI. The metabolite M2 was obtained
from semipreparative incubations, purified by HPLC and analyzed by NMR on a
Bruker 500 MHz.
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Human liver microsomes : Incubation with human liver microsomes showed that
metabolite M2 was formed in presence of NADPH. Control without NADPH were
blank. Its formation was inhibited by benzyl imidazole (50 µM) implicating cytochrome
P450 catalysis. An impurity, 2-hydroxy-fluindione slowly increased on storage of
incubations. It’s a known oxidation product of fluindione by air.
Recombinant human P450: The formation of M2 was studied using insect cell
microsomes expressing recombinant CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1,
3A4 and 3A5. CYP1A2, 2B6, 2C9, 2D6, 3A4 and 3A5 could make this metabolite.
CYP2C9 and CYP1A2 had best affinities (about 30 µM) as shown in Table1.
Table 1 : Kinetic parameters for M2 formation by human P450 and liver microsomes
CYP or microsomes 1A2 2B6 2C9 2D6 3A4 Pool HLM
Km (µM) 40 489 33 656 311 143
Vm (nmol/min/nmol P450) 2.2 3.7 3.2 5.9 8.9 0.3
Vm/Km (L /min/nmol) 55 7.6 100 9 29 2
Synthesis: 13C6 labeled fluindione was synthetized from 13C6 labeled phthalic
anhydride (6). 3-(4-Fluoro-phenyl)-4-hydroxy-coumarin (7), 3-(4-Fluorophenyl)-
4-hydroxy-isocoumarin (8), 2-(4-hydroxyphenyl)-indane-1,3-dione (9) and 2-
hydroxy-fluindione (10) were synthetised by modification of known methods.
RESULTS :
In vivo : Rats were treated by 5 and 20 mg/kg fluindione 13C6/12C 1/1 mixture
Plasma : Analysis of plasma showed doubly labeled compounds with a
doublet in the mass spectrum : fluindione F (m/z = 239/245, C15H9O2-) and
metabolites: M1 (m/z = 237.0558/243.0760) corresponding to defluorination and
hydroxylation, and identified by comparison with an authentic to 2-(4-
hydroxyphenyl)-indane-1,3-dione and M2 (m/z = 255.0467/ 261.0668)
corresponding to C15H8O3F thus addition of an oxygen to fluindione. M2 was
less polar than fluindione and had a UV spectrum nearly superimposable with that
of fluindione (see below). A minor metabolite M3 also less (m/z =
253.0499/259.0700) corresponding to C15H9O4 thus fluindione defluorinated
and dihydroxylated .
Urine : Analysis of urine showed the same metabolites in low amount plus
series of more polar metabolites. They corresponded to sulfate esters: S2 was
relatively abondant ( m/z = 335.0006, C15H8O6FS ) its MS and MS2 showed
fragmentation at m/z = 255.0446 with loss of SO3. S3 had a m/z = 333.0046 in
MS and its MS2 spectrum showed fragmentation at m/z = 253.0499 with loss of
SO3. Thus we believe that S2 and S3 are the sufate esters of M2 and M3.
Plasma and Human Urine: A poly-medicated volunteer took orally 10 mg of
fluindione. Fluindione could be detected in plasma at 1, 2 and 6 hours. However
the metabolites could only be found in very low amount (limit of detection).
Figure 2 : Selected mass and UVspectra of fluindione and its metabolites
Synthesis of some potential metabolites and 13C6 labeled fluindione:
In order to characterize M2, the chemical synthesis of several candidate molecules was
performed: 2-hydroxy-fluindione, 2-(4’-fluorophenyl)-4-hydroxy-coumarin, 2-(4’-fluorophen
yl)-4-hydroxy-isocoumarin, 4’-hydroxy-phenindione . Metabolite M2 did not correspond to
any of the synthetized products. However M1 was identified as 4’-hydroxy-phenindione .
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Studies in Vitro:
Rat liver microsomes: Incubation of rat liver microsomes with 100 µM
fluindione showed formation of a major metabolite identical to M2 with a m/z =
255.0446 and a UV spectrum identical to that of fluindione. A semi-preparative
incubation using 60 mL incubation medium allowed to isolate by HPLC about 0.3
mg of metabolite. Its proton NMR spectrum showed a disymetrical molecule
with all the ring A proton different. The fluorophenyl ring was not modified. We
could not abtain a 13C spectrum for further identification. M2 was compared to
synthetic 3-(4-fluoro-phenyl)-4-hydroxy-coumarin, 3-(4-fluoro-phenyl)-4-
hydroxy-isocoumarin, 2-(4-hydroxy-phenyl)-indane-1,3-dione and 2-hydroxy-
fluindione which were all different. Thus until now we don’t have the structure of
M2.
Figure 1 : Proton NMR spectra of fluindione and metabolite M2
References: 1) Molho D. and Boschetti E. (1963), French Patent 1.369.396 2) Geiger K et al.US patent (1963),  US patent 3,090,813. 3) Shapiro L. et al. (1961) J Org Chem 26, 3580-81. 4) Comets E, et al. 
(2012) Clin Pharmacol Ther. 91(5):777-86 and references therein. 5) Moreau C, et al. (2014) Thromb Haemost. 111(4):705-12.  6) Oskaja, V.and Vanags, G. (1961) Lat PSR Zin Akad Vestis3, 67-76. 7) Zhou 
ZZ et al. (2013) Chem Pharm Bull (Tokyo) 61(11), pp 1166-1172. 8) Faizi DJ, et  al. (2016)  J Am Chem Soc. 138(7):2126-9. 9) Marinov M. et al. (2014)  J. Structural Chem. 55,  3, 446-455. 
.
CONCLUSION :
- Fluindione is metabolized in rat and human microsome to oxidized metabolites
corresponding to either an oxidation of the B ring of the indanedione (M2, 
m/z=255), or oxidation of the fluorophenyl with defluorination (M1, m/z =237) 
and both reactions (M3, m/z = 253).
- These oxidations are P450 dependent and human recombinant CYP2C9 and 
CYP1A2 have good affinities for formation of M2 also formed by CYP3A4.
In vivo in rat, the primary metabolites are found in plasma, but in urine one find
the sulfate esters of M2 and M3.
- A tentative experiment in a human volunteer showed only fluindione and M2 in 
plasma and only traces of fluindione in urine. 
- The metabolism of fluindione is mediated by several cytochrome P450 which
explain why CYP2C9 is not a genetic determinant for its posology.
- Finally the structure of M2 and M3 remain to be characterized.
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